AngioDynamics (ANGO)
Nasdaq Market Closed
AngioDynamics, Inc. is a medical technology company that develops, manufactures, and sells devices used in vascular access, peripheral vascular intervention, oncology, and surgical care. Its products are designed for physicians and hospital-based healthcare teams that treat conditions such as peripheral vascular disease, blood clots, cancerous tumors, and complications requiring image-guided procedures.
The company’s portfolio spans both established medical device categories and higher-growth medtech platforms. In vascular care, AngioDynamics offers products used to access, maintain, and treat blood vessels, including catheters, ports, and related devices. Its peripheral vascular products support minimally invasive procedures intended to restore or improve blood flow, while its oncology and surgery offerings include technologies used in ablation and other interventional treatments.
AngioDynamics sells primarily to hospitals, ambulatory surgery centers, and other healthcare providers, with the United States accounting for the majority of revenue. The company competes in markets where clinical performance, physician adoption, reimbursement, and hospital purchasing decisions are key commercial drivers. Its strategy centers on serving procedural specialists with devices that can improve workflow, enable less invasive treatment, or address areas of unmet clinical need.
As a listed medical device company, AngioDynamics is exposed to regulatory requirements, product innovation cycles, and healthcare spending trends. Its performance depends on procedure volumes, the success of newer technologies, and its ability to maintain relevance across competitive vascular and interventional oncology markets.
Last updated
- Market Cap
- 497.07M
- P/E
- —
- P/FCF
- —
- P/S
- 1.58
- Enterprise Value
- 459.26M
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 14 PLAZA DRIVE, LATHAM, NY, 12110
Atherectomy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036
3 Stocks Insiders Are Buying Heavily in October and Why
AngioDynamics stock target raised on growth prospects - Investing.com
U.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) Settles Patent Litigations With BD
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors
Why AngioDynamics (ANGO) Dipped More Than Broader Market Today
AngioDynamics (ANGO) Gains But Lags Market: What You Should Know
Here's Why AngioDynamics (ANGO) Gained But Lagged the Market Today
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
AngioDynamics (ANGO) Stock Sinks As Market Gains: Here's Why
AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment
AngioDynamics (ANGO) Q2 Earnings Top Estimates, Revenues Miss
AngioDynamics (ANGO) Reports Q2 Loss, Misses Revenue Estimates
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
Why AngioDynamics (ANGO) Outpaced the Stock Market Today
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 497.07M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 459.26M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.87
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.58
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -79.09
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.46
- EPS
- -0.76
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 111.75
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -1.01M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -18.11%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -12.04%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.35
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.47
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.57
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 285.04K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 12.03
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 78.42M | 79.43M | 75.71M | 80.16M | 72M |
| Gross profit | 41.48M | 44.78M | 41.86M | 42.22M | 38.86M |
| Operating income | -12.95M | -6.13M | -10.66M | -5.79M | -9.97M |
| EBITDA | -838K | -378K | -4.64M | 45K | -369K |
| Net income | -8.08M | -6.35M | -10.9M | -6.05M | -4.41M |
| Basic EPS | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 |
| Diluted EPS | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 260.68M | 269.68M | 265.64M | 280.14M | 285.42M |
| Total liabilities | 87.32M | 93.35M | 86.79M | 97.17M | 99.55M |
| Total equity | 173.36M | 176.33M | 178.86M | 182.97M | 185.87M |
| Cash & equivalents | 37.81M | 41.64M | 38.76M | 55.89M | 44.76M |
| Current assets | 155.55M | 161.35M | 156.66M | 168.32M | 172.27M |
| Current liabilities | 66.07M | 71.96M | 68.28M | 76.2M | 77.97M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | -3.11M | 4.66M | -15.91M | 18.81M | -13.16M |
| Investing cash flow | -1.51M | -1.62M | -1.55M | -2.62M | -3.19M |
| Financing cash flow | 621K | -92K | 143K | -5.77M | 7.15M |
| Change in cash | -3.83M | 2.88M | -17.13M | 11.13M | -9.33M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| edgar index | 10-Q — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G — ANGIODYNAMICS INC | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| edgar index | 10-Q — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | S-8 — ANGIODYNAMICS INC | View Filing | |
| form 4 | Form 4 — Weiss Lawrence T | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| form 4 | Form 4 — Trowbridge Stephen A | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| form 4 | Form 4 — Clemmer James C | View Filing | |
| edgar index | 8-K — ANGIODYNAMICS INC | View Filing | |
| edgar index | 10-Q — ANGIODYNAMICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — ANGIODYNAMICS INC | View Filing | |
| edgar index | DEFA14A — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — ANGIODYNAMICS INC | View Filing | |
| edgar index | SCHEDULE 13G — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| form 4 | Form 4 — Campbell Chad Thomas | View Filing | |
| form 4 | Form 4 — Nighan Warren JR | View Filing | |
| form 4 | Form 4 — Trowbridge Stephen A | View Filing | |
| form 4 | Form 4 — Campbell Chad Thomas | View Filing | |
| form 4 | Form 4 — Clemmer James C | View Filing | |
| form 4 | Form 4 — Clemmer James C | View Filing | |
| form 4 | Form 4 — Nighan Warren JR | View Filing | |
| form 4 | Form 4 — Piccinini Laura | View Filing | |
| form 4 | Form 4 — Trowbridge Stephen A | View Filing | |
| form 4 | Form 4 — Campbell Chad Thomas | View Filing | |
| form 4 | Form 4 — Clemmer James C | View Filing | |
| form 4 | Form 4 — Clemmer James C | View Filing | |
| form 4 | Form 4 — Nighan Warren JR | View Filing | |
| form 4 | Form 4 — Piccinini Laura | View Filing | |
| form 4 | Form 4 — Trowbridge Stephen A | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 4 — ANGIODYNAMICS INC | View Filing | |
| edgar index | 10-K — ANGIODYNAMICS INC | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G — ANGIODYNAMICS INC | View Filing | |
| form 4 | Form 4 — Piccinini Laura | View Filing |